SARS CoV 2 News and Research

RSS

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the renin-angiotensin system on the clinical outcomes of individuals with coronavirus disease 2019 (COVID-19).

21 Nov 2022

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

A third COVID-19 vaccine dose in this patients with blood cancers could enhance their antibody responses against SARS-CoV-2

21 Nov 2022

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

Researchers demonstrated a viral amplification procedure to isolate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants.

21 Nov 2022

Increase in Candida auris infections among EU/EEA nations between 2020 and 2021

Researchers evaluated the trends in Candida auris infections among European Union/European Economic Area (EU/EUA) nations between 2020 and 2021.

21 Nov 2022

What is the association between particulate matter exposure and SARS-CoV-2 infections?

In a new study, researchers assessed the association between particulate matter ≤2.5mm (PM2.5) exposure and SARS-CoV-2 infection and severity outcomes such as hospitalizations and deaths.

21 Nov 2022

Chitin-immobilized nanobodies for SARS-CoV-2 detection

Researchers demonstrated a novel strategy to detect SARS-CoV-2 using chitin-immobilized nanobodies.

21 Nov 2022

SARS-CoV-2 infection and mRNA vaccination prime transcriptionally distinct CD4+ T cell memory landscapes

Researchers reported that SARS-CoV-2 infection and mRNA vaccination induce distinct memory T cells.

21 Nov 2022

Enormous rise in Acinetobacter bloodstream infection cases in initial two years of COVID-19

In a new study, researchers investigated Acinetobacter species bloodstream infection (BSI) case counts from a subset of laboratory data continuously reported during the initial two years of SARS-CoV-2 infections, i.e., from 2020 to 2021.

21 Nov 2022

Frozen and viable: successful culture of replicating SARS-CoV-2 from hospital aerosol samples after freezing

Researchers demonstrated the presence of infectious SARS-CoV-2 in samples from the hospital rooms of SARS-CoV-2-infected patients.

21 Nov 2022

Rutgers scientists develop new approach to effectively shut down viral infections

Rutgers scientists have developed a new approach to stopping viral infections: a so-called live-attenuated, replication-defective DNA virus vaccine that uses a compound known as centanamycin to generate an altered virus for vaccine development.

20 Nov 2022

Scientists explore bat sarbecovirus isolation in Japan

Researchers performed bat sarbecovirus isolation experiments using Rhinolophus cornutus bats from several regions in Japan that were phylogenetically situated in the same cluster of viruses related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Nov 2022

β-cyclodextrin family found to be promising and cost-effective antiviral agents against SARS-CoV-2

Researchers identified β-cyclodextrins (β-CDs) as a safe and cost-effective drug against SARS-CoV-2 with a broad spectrum of activity.

18 Nov 2022

Intermediate levels of indoor relative humidity shown to improve COVID-19 outcomes globally

In a new study, researchers found that indoor relative humidity modulates the severity of COVID-19 outbreaks, and intermediate RHs between 40 to 60% are robustly associated with better COVID-19 outcomes.

18 Nov 2022

World Antimicrobial Awareness Week: Preventing Antimicrobial Resistance Together

In this interview, News-Medical talks to Dr Javier Yugueros-Marcos, Head of the Antimicrobial Resistance and Veterinary Products Department at the World Organisation for Animal Health, about how the world can work together to promote the sustainable and responsible use of antimicrobials.

18 Nov 2022

SARS CoV 2 News and Research

Study finds no benefits from angiotensin receptor blocker treatment for COVID-19

Additional mRNA COVID vaccine doses could salvage antibody responses in blood cancer patients

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

Increase in Candida auris infections among EU/EEA nations between 2020 and 2021

What is the association between particulate matter exposure and SARS-CoV-2 infections?

Chitin-immobilized nanobodies for SARS-CoV-2 detection

SARS-CoV-2 infection and mRNA vaccination prime transcriptionally distinct CD4+ T cell memory landscapes

Enormous rise in Acinetobacter bloodstream infection cases in initial two years of COVID-19

Frozen and viable: successful culture of replicating SARS-CoV-2 from hospital aerosol samples after freezing

Rutgers scientists develop new approach to effectively shut down viral infections

Scientists explore bat sarbecovirus isolation in Japan

β-cyclodextrin family found to be promising and cost-effective antiviral agents against SARS-CoV-2

Intermediate levels of indoor relative humidity shown to improve COVID-19 outcomes globally

World Antimicrobial Awareness Week: Preventing Antimicrobial Resistance Together

How gut microbes influence immune response to SARS-CoV-2

Study identifies risk factors and symptom clusters associated with long-COVID

COVID-19 carries a much higher risk of epilepsy and seizures than influenza

Bispecific antibodies neutralize Sarbecoviruses with increased breadth and potency

WHO releases new data on worldwide influenza activity

What is the immune protection generated by SARS-CoV-2 Delta and Omicron BA.1 and BA.2 against Omicron BA.4 and BA.5?

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News